Baseline characteristics of the study population (N = 22)
| Characteristic . | Median [range] or n (%) . |
|---|---|
| Age, y | 46 [29-59] |
| Prior history of solid tumor* | 3 (14) |
| Therapy-related AML | 2 (9) |
| White blood cells, ×109/L | 8.4 [0.6-33.5] |
| Peripheral blood blasts, ×109/L | 4.2 [0-200.8] |
| Peripheral blood blasts, % | 46 [0-94] |
| Bone marrow blasts, % | 58 [25-93] |
| Cytogenetics | |
| Diploid | 7 (32) |
| t(8;21) | 2 (9) |
| inv(16) | 3 (14) |
| 11q23 rearrangement | 1 (5) |
| −7 | 1 (5) |
| inv(3) | 1 (5) |
| Complex | 3 (14) |
| Other abnormalities | 3 (14) |
| Insufficient metaphases | 1 (5) |
| Mutations (bone marrow) | |
| ASXL1 | 1 (5) |
| CEBPA† | 3 (14) |
| DNMT3A | 2 (9) |
| FLT3-ITD† | 6 (27) |
| FLT3-TKD | 3 (14) |
| KIT | 2 (9) |
| IDH1 | 2 (9) |
| IDH2 | 2 (9) |
| KRAS | 2 (9) |
| MPL | 1 (5) |
| NPM1 | 3 (14) |
| NRAS | 4 (18) |
| RUNX1 | 2 (9) |
| TET2 | 1 (5) |
| TP53 | 2 (9) |
| WT1 | 2 (9) |
| Characteristic . | Median [range] or n (%) . |
|---|---|
| Age, y | 46 [29-59] |
| Prior history of solid tumor* | 3 (14) |
| Therapy-related AML | 2 (9) |
| White blood cells, ×109/L | 8.4 [0.6-33.5] |
| Peripheral blood blasts, ×109/L | 4.2 [0-200.8] |
| Peripheral blood blasts, % | 46 [0-94] |
| Bone marrow blasts, % | 58 [25-93] |
| Cytogenetics | |
| Diploid | 7 (32) |
| t(8;21) | 2 (9) |
| inv(16) | 3 (14) |
| 11q23 rearrangement | 1 (5) |
| −7 | 1 (5) |
| inv(3) | 1 (5) |
| Complex | 3 (14) |
| Other abnormalities | 3 (14) |
| Insufficient metaphases | 1 (5) |
| Mutations (bone marrow) | |
| ASXL1 | 1 (5) |
| CEBPA† | 3 (14) |
| DNMT3A | 2 (9) |
| FLT3-ITD† | 6 (27) |
| FLT3-TKD | 3 (14) |
| KIT | 2 (9) |
| IDH1 | 2 (9) |
| IDH2 | 2 (9) |
| KRAS | 2 (9) |
| MPL | 1 (5) |
| NPM1 | 3 (14) |
| NRAS | 4 (18) |
| RUNX1 | 2 (9) |
| TET2 | 1 (5) |
| TP53 | 2 (9) |
| WT1 | 2 (9) |
ITD, internal tandem duplication; TKD, tyrosine kinase domain.
Prior malignancies included breast cancer, soft tissue sarcoma, and diffuse large B-cell lymphoma in 1 patient each.
CEBPA and FLT3-ITD mutations were not included in the 28-gene NGS mutation panel and were detected through other standard-of-care molecular testing.